Numient

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

levodopa, carbidopa

Available from:

Amneal Pharma Europe Ltd

ATC code:

N04BA02

INN (International Name):

levodopa, carbidopa

Therapeutic group:

Anti-parkinsonska zdravila

Therapeutic area:

Parkinsonova bolezen

Therapeutic indications:

Simptomatsko zdravljenje odraslih bolnikov s Parkinsonovo boleznijo.

Product summary:

Revision: 3

Authorization status:

Umaknjeno

Authorization date:

2015-11-19

Patient Information leaflet

                                29
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Numient 95/23,75 mg
Numient 145/36,25 mg
Numient 195/48,75 mg
Numient 245/61,25 mg
30
PODATKI NA PRIMARNI OVOJNINI
STEKLENICA/HDPE
1.
IME ZDRAVILA
Numient 95 mg/23,75 mg trda kapsula s prirejenim sproščanjem
Numient 145 mg/36,25 mg trda kapsula s prirejenim sproščanjem
Numient 195 mg/48,75 mg trda kapsula s prirejenim sproščanjem
Numient 245 mg/61,25 mg trda kapsula s prirejenim sproščanjem
levodopa/karbidopa
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena kapsula vsebuje 95 mg levodope in 23,75 mg karbidope (v obliki
monohidrata).
Ena kapsula vsebuje 145 mg levodope in 36,25 mg karbidope (v obliki
monohidrata).
Ena kapsula vsebuje 195 mg levodope in 48,75 mg karbidope (v obliki
monohidrata).
Ena kapsula vsebuje 245 mg levodope in 61,25 mg karbidope (v obliki
monohidrata).
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
25 trdih kapsul s prirejenim sproščanjem
100 trdih kapsul s prirejenim sproščanjem
240 trdih kapsul s prirejenim sproščanjem
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
Kapsule pogoltnite cele in jih ne žvečite.
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
Po odprtju vsebnika uporabite zdravilo v 90 dneh.
31
Odprto:
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 30 °C. Shranjujte v originalni ovojnini
za zagotovitev zaščite pred
svetlobo in vlago.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Logotip družbe Amneal Pharma.
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
Numient 95 mg/23,75 mg trda kapsula s prirejenim sproščanjem
EU/1/15/1044/001 (25 trdih kapsul s prirejenim sproščanjem)
EU/1/15/1044/002 (100 trdih kapsul s prireje
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Numient 95 mg/23,75 mg trda kapsula s prirejenim sproščanjem
Numient 145 mg/36,25 mg trda kapsula s prirejenim sproščanjem
Numient 195 mg/48,75 mg trda kapsula s prirejenim sproščanjem
Numient 245 mg/61,25 mg trda kapsula s prirejenim sproščanjem
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
95 mg/23,75 mg trda kapsula s prirejenim sproščanjem
Ena kapsula vsebuje 95 mg levodope in 23,75 mg karbidope (v obliki
monohidrata).
145 mg/36,25 mg trda kapsula s prirejenim sproščanjem
Ena kapsula vsebuje 145 mg levodope in 36,25 mg karbidope (v obliki
monohidrata).
195 mg/48,75 mg trda kapsula s prirejenim sproščanjem
Ena kapsula vsebuje 195 mg levodope in 48,75 mg karbidope (v obliki
monohidrata).
245 mg/61,25 mg trda kapsula s prirejenim sproščanjem
Ena kapsula vsebuje 245 mg levodope in 61,25 mg karbidope (v obliki
monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
trda kapsula s prirejenim sproščanjem
95 mg/23,75 mg trda kapsula s prirejenim sproščanjem
Velikosti 18 × 6 mm z belim telesom in modrim pokrovčkom, z
vtisnjenima oznakama »IPX066« in
»95« z modrim črnilom.
145 mg/36,25 mg trda kapsula s prirejenim sproščanjem
Velikosti 19 × 7 mm s svetlo modrim telesom in modrim pokrovčkom, z
vtisnjenima oznakama
»IPX066« in »145« z modrim črnilom.
195 mg/48,75 mg trda kapsula s prirejenim sproščanjem
Velikosti 24 × 8 mm z rumenim telesom in modrim pokrovčkom, z
vtisnjenima oznakama »IPX066«
in »195« z modrim črnilom.
245 mg/61,25 mg trda kapsula s prirejenim sproščanjem
Velikosti 23 × 9 mm z modrim telesom in modrim pokrovčkom, z
vtisnjenima oznakama »IPX066« in
»245« z modrim črnilom.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Numient je indicirano za simptomatsko zdravljenje
Parkinsonove bolezni pri odraslih
bolnikih._ _
3
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Zdravilo Numient je priporočljivo odmerjati peroralno, približno
vsakih 6 ur. Odmerjanje
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 09-08-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 09-08-2018
Public Assessment Report Public Assessment Report Bulgarian 25-11-2015
Patient Information leaflet Patient Information leaflet Spanish 09-08-2018
Public Assessment Report Public Assessment Report Spanish 25-11-2015
Patient Information leaflet Patient Information leaflet Czech 09-08-2018
Public Assessment Report Public Assessment Report Czech 25-11-2015
Patient Information leaflet Patient Information leaflet Danish 09-08-2018
Public Assessment Report Public Assessment Report Danish 25-11-2015
Patient Information leaflet Patient Information leaflet German 09-08-2018
Public Assessment Report Public Assessment Report German 25-11-2015
Patient Information leaflet Patient Information leaflet Estonian 09-08-2018
Public Assessment Report Public Assessment Report Estonian 25-11-2015
Patient Information leaflet Patient Information leaflet Greek 09-08-2018
Public Assessment Report Public Assessment Report Greek 25-11-2015
Patient Information leaflet Patient Information leaflet English 09-08-2018
Public Assessment Report Public Assessment Report English 25-11-2015
Patient Information leaflet Patient Information leaflet French 09-08-2018
Public Assessment Report Public Assessment Report French 25-11-2015
Patient Information leaflet Patient Information leaflet Italian 09-08-2018
Public Assessment Report Public Assessment Report Italian 25-11-2015
Patient Information leaflet Patient Information leaflet Latvian 09-08-2018
Public Assessment Report Public Assessment Report Latvian 25-11-2015
Patient Information leaflet Patient Information leaflet Lithuanian 09-08-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 09-08-2018
Public Assessment Report Public Assessment Report Lithuanian 25-11-2015
Patient Information leaflet Patient Information leaflet Hungarian 09-08-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 09-08-2018
Public Assessment Report Public Assessment Report Hungarian 25-11-2015
Patient Information leaflet Patient Information leaflet Maltese 09-08-2018
Public Assessment Report Public Assessment Report Maltese 25-11-2015
Patient Information leaflet Patient Information leaflet Dutch 09-08-2018
Public Assessment Report Public Assessment Report Dutch 25-11-2015
Patient Information leaflet Patient Information leaflet Polish 09-08-2018
Public Assessment Report Public Assessment Report Polish 25-11-2015
Patient Information leaflet Patient Information leaflet Portuguese 09-08-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 09-08-2018
Public Assessment Report Public Assessment Report Portuguese 25-11-2015
Patient Information leaflet Patient Information leaflet Romanian 09-08-2018
Public Assessment Report Public Assessment Report Romanian 25-11-2015
Patient Information leaflet Patient Information leaflet Slovak 09-08-2018
Public Assessment Report Public Assessment Report Slovak 25-11-2015
Patient Information leaflet Patient Information leaflet Finnish 09-08-2018
Public Assessment Report Public Assessment Report Finnish 25-11-2015
Patient Information leaflet Patient Information leaflet Swedish 09-08-2018
Public Assessment Report Public Assessment Report Swedish 25-11-2015
Patient Information leaflet Patient Information leaflet Norwegian 09-08-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 09-08-2018
Patient Information leaflet Patient Information leaflet Icelandic 09-08-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 09-08-2018
Patient Information leaflet Patient Information leaflet Croatian 09-08-2018
Public Assessment Report Public Assessment Report Croatian 25-11-2015

Search alerts related to this product

View documents history